Recommended for patients with mild to moderate OA (Kellgren grade 2 or 3)²¹
Can be considered for use before or used concurrently with COX-2 inhibitors or NSAIDs²¹
May reduce patient use of NSAIDs²⁴
Demonstrated pain relief compared with intra-articular corticosteroid (6-methylprednisolone acetate) over time¹⁴^,³⁶

Recommended before, during, and after COX-2 and NSAID treatment¹⁶^,²¹

Adapted from ACR guidelines and recommendations of the Hyaluronan Consensus Group* of orthopaedic surgeons

*Sponsored by sanofi-aventis U.S.

Important Safety Information for HYALGAN®

HYALGAN® is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpha-rmacologic therapy, and to simple analgesics, eg, acetaminophen
HYALGAN® is contraindicated in patients with known hypersensitivity to hyaluronate preparations. Intra-articular injections are contraindicated in cases of past and present infections or skin diseases in the area of the injection site
The effectiveness of a single treatment cycle of less than 3 injections has not been established
In the US clinical trial of 495 patients, the only adverse event showing statistical significance vs placebo was injection-site pain
Other adverse events included gastrointestinal complaints, headache, local ecchymosis and rash, local joint pain and swelling, and local pruritus. However, the incidence of these events was similar in the HYALGAN®-treated and placebo groups
In other clinical studies, the frequency and severity of adverse events occurring during repeat treatment cycles did not increase over that reported for a single treatment cycle

When to Use HYALGAN®